SCP
LCTX icon

Seizert Capital Partners’s Lineage Cell Therapeutics LCTX Stock Holding History

Seizert Capital Partners’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-24,161
Closed -$73K – 217
2014
Q4 		$73K Sell
24,161
-371
-2% -$1K ﹤0.01% 210
2014
Q3 		$62K Sell
24,532
-372
-1% -$896 ﹤0.01% 205
2014
Q2 		$61K Hold
24,904
– – ﹤0.01% 206
2014
Q1 		$66K Hold
24,904
– – ﹤0.01% 204
2013
Q4 		$72K Hold
24,904
– – ﹤0.01% 205
2013
Q3 		$76K Hold
24,904
– – ﹤0.01% 200
2013
Q2 		$80K Buy
+24,904
New +$79.8K ﹤0.01% 199

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $302M AUM 117.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Seizert Capital Partners's LCTX Position: Q1 2015 in Review

Seizert Capital Partners sold out of Lineage Cell Therapeutics (LCTX) in Q1 2015, closing a stake of 24,161 shares — an estimated $73K sold.

Seizert Capital Partners first reported a position in LCTX in Q2 2013 and held it in 7 quarters. The position peaked at $80K in Q2 2013. 69 funds tracked by Wall St. Rank hold LCTX as of Q1 2015.

  • Seizert Capital Partners reported no remaining Lineage Cell Therapeutics position as of Q1 2015 after selling out during the quarter.
  • Seizert Capital Partners sold 24,161 Lineage Cell Therapeutics shares in Q1 2015, an estimated $73K.
  • Seizert Capital Partners first reported a position in Lineage Cell Therapeutics in Q2 2013 and held it in 7 quarters.
  • Seizert Capital Partners's Lineage Cell Therapeutics position peaked at $80K in Q2 2013.
  • 69 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2015.

Based on Seizert Capital Partners's 13F filing for Q1 2015, filed 4 May 2015.